

Thomas S Harrison

List of Publications by Citations

Source: <https://exaly.com/author-pdf/8913642/thomas-s-harrison-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

169
papers

10,877
citations

53
h-index

102
g-index

183
ext. papers

13,233
ext. citations

9.6
avg, IF

5.95
L-index

#	Paper	IF	Citations
169	Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. <i>Clinical Infectious Diseases</i> , 2010 , 50, 291-322	11.6	1683
168	Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. <i>Clinical Infectious Diseases</i> , 2020 , 71, 1367-1376	11.6	607
167	Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. <i>Lancet, The</i> , 2004 , 363, 1764-7	40	368
166	High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. <i>New England Journal of Medicine</i> , 2014 , 371, 1599-608	59.2	301
165	Cryptococcal meningitis. <i>British Medical Bulletin</i> , 2004 , 72, 99-118	5.4	251
164	Screening for cryptococcal antigenemia in patients accessing an antiretroviral treatment program in South Africa. <i>Clinical Infectious Diseases</i> , 2009 , 48, 856-62	11.6	244
163	Determinants of mortality in a combined cohort of 501 patients with HIV-associated Cryptococcal meningitis: implications for improving outcomes. <i>Clinical Infectious Diseases</i> , 2014 , 58, 736-45	11.6	234
162	Fungal burden, early fungicidal activity, and outcome in cryptococcal meningitis in antiretroviral-naive or antiretroviral-experienced patients treated with amphotericin B or fluconazole. <i>Clinical Infectious Diseases</i> , 2007 , 45, 76-80	11.6	230
161	Evaluation of a novel point-of-care cryptococcal antigen test on serum, plasma, and urine from patients with HIV-associated cryptococcal meningitis. <i>Clinical Infectious Diseases</i> , 2011 , 53, 1019-23	11.6	229
160	Cryptococcal meningitis: epidemiology, immunology, diagnosis and therapy. <i>Nature Reviews Neurology</i> , 2017 , 13, 13-24	15	222
159	High-dose amphotericin B with flucytosine for the treatment of cryptococcal meningitis in HIV-infected patients: a randomized trial. <i>Clinical Infectious Diseases</i> , 2008 , 47, 123-30	11.6	209
158	Fungal infections in HIV/AIDS. <i>Lancet Infectious Diseases, The</i> , 2017 , 17, e334-e343	25.5	201
157	Adult meningitis in a setting of high HIV and TB prevalence: findings from 4961 suspected cases. <i>BMC Infectious Diseases</i> , 2010 , 10, 67	4	193
156	Adjunctive interferon- γ immunotherapy for the treatment of HIV-associated cryptococcal meningitis: a randomized controlled trial. <i>Aids</i> , 2012 , 26, 1105-13	3.5	192
155	The Case for Adopting the "Species Complex" Nomenclature for the Etiologic Agents of Cryptococcosis. <i>MSphere</i> , 2017 , 2,	5	185
154	Antifungal Combinations for Treatment of Cryptococcal Meningitis in Africa. <i>New England Journal of Medicine</i> , 2018 , 378, 1004-1017	59.2	183
153	Cryptococcus neoformans resides in an acidic phagolysosome of human macrophages. <i>Infection and Immunity</i> , 1999 , 67, 885-90	3.7	177

152	Symptomatic relapse of HIV-associated cryptococcal meningitis after initial fluconazole monotherapy: the role of fluconazole resistance and immune reconstitution. <i>Clinical Infectious Diseases</i> , 2006 , 43, 1069-73	11.6	174
151	Independent association between rate of clearance of infection and clinical outcome of HIV-associated cryptococcal meningitis: analysis of a combined cohort of 262 patients. <i>Clinical Infectious Diseases</i> , 2009 , 49, 702-9	11.6	166
150	Cryptococcal meningitis screening and community-based early adherence support in people with advanced HIV infection starting antiretroviral therapy in Tanzania and Zambia: an open-label, randomised controlled trial. <i>Lancet, The</i> , 2015 , 385, 2173-82	40	151
149	Dose response effect of high-dose fluconazole for HIV-associated cryptococcal meningitis in southwestern Uganda. <i>Clinical Infectious Diseases</i> , 2008 , 47, 1556-61	11.6	151
148	Immune reconstitution inflammatory syndrome in HIV-associated cryptococcal meningitis: a prospective study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009 , 51, 130-4	3.1	146
147	Combination flucytosine and high-dose fluconazole compared with fluconazole monotherapy for the treatment of cryptococcal meningitis: a randomized trial in Malawi. <i>Clinical Infectious Diseases</i> , 2010 , 50, 338-44	11.6	142
146	Relationship of cerebrospinal fluid pressure, fungal burden and outcome in patients with cryptococcal meningitis undergoing serial lumbar punctures. <i>Aids</i> , 2009 , 23, 701-6	3.5	129
145	IFN-gamma at the site of infection determines rate of clearance of infection in cryptococcal meningitis. <i>Journal of Immunology</i> , 2005 , 174, 1746-50	5.3	129
144	Cryptococcal meningitis: improving access to essential antifungal medicines in resource-poor countries. <i>Lancet Infectious Diseases, The</i> , 2013 , 13, 629-37	25.5	112
143	Comparison of the early fungicidal activity of high-dose fluconazole, voriconazole, and flucytosine as second-line drugs given in combination with amphotericin B for the treatment of HIV-associated cryptococcal meningitis. <i>Clinical Infectious Diseases</i> , 2012 , 54, 121-8	11.6	102
142	Cost effectiveness of cryptococcal antigen screening as a strategy to prevent HIV-associated cryptococcal meningitis in South Africa. <i>PLoS ONE</i> , 2013 , 8, e69288	3.7	96
141	Chloroquine induces human mononuclear phagocytes to inhibit and kill <i>Cryptococcus neoformans</i> by a mechanism independent of iron deprivation. <i>Journal of Clinical Investigation</i> , 1997 , 100, 1640-6	15.9	93
140	The phenotype of the <i>Cryptococcus</i> -specific CD4+ memory T-cell response is associated with disease severity and outcome in HIV-associated cryptococcal meningitis. <i>Journal of Infectious Diseases</i> , 2013 , 207, 1817-28	7	91
139	Efficient phagocytosis and laccase activity affect the outcome of HIV-associated cryptococcosis. <i>Journal of Clinical Investigation</i> , 2014 , 124, 2000-8	15.9	88
138	Cerebrospinal fluid cytokine profiles predict risk of early mortality and immune reconstitution inflammatory syndrome in HIV-associated cryptococcal meningitis. <i>PLoS Pathogens</i> , 2015 , 11, e1004754	7.6	86
137	Flucytosine and cryptococcosis: time to urgently address the worldwide accessibility of a 50-year-old antifungal. <i>Journal of Antimicrobial Chemotherapy</i> , 2013 , 68, 2435-44	5.1	81
136	Cryptococcal Antigen Screening in Patients Initiating ART in South Africa: A Prospective Cohort Study. <i>Clinical Infectious Diseases</i> , 2016 , 62, 581-587	11.6	74
135	Clinical application of whole-genome sequencing to inform treatment for multidrug-resistant tuberculosis cases. <i>Journal of Clinical Microbiology</i> , 2015 , 53, 1473-83	9.7	74

134	Cryptococcus neoformans ex vivo capsule size is associated with intracranial pressure and host immune response in HIV-associated cryptococcal meningitis. <i>Journal of Infectious Diseases</i> , 2014 , 209, 74-82	7	74
133	Pulmonary cryptococcosis. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2008 , 29, 141-50	3.9	71
132	Multidrug-resistant tuberculosis (MDR-TB) treatment in the UK: a study of injectable use and toxicity in practice. <i>Journal of Antimicrobial Chemotherapy</i> , 2011 , 66, 1815-20	5.1	70
131	Toxicity of Amphotericin B Deoxycholate-Based Induction Therapy in Patients with HIV-Associated Cryptococcal Meningitis. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 59, 7224-31	5.9	69
130	The Cryptococcus neoformans Titan cell is an inducible and regulated morphotype underlying pathogenesis. <i>PLoS Pathogens</i> , 2018 , 14, e1006978	7.6	69
129	High ongoing burden of cryptococcal disease in Africa despite antiretroviral roll out. <i>Aids</i> , 2009 , 23, 1182-3	3	69
128	Genotypic Diversity Is Associated with Clinical Outcome and Phenotype in Cryptococcal Meningitis across Southern Africa. <i>PLoS Neglected Tropical Diseases</i> , 2015 , 9, e0003847	4.8	65
127	Association of mannose-binding lectin deficiency with acute invasive aspergillosis in immunocompromised patients. <i>Clinical Infectious Diseases</i> , 2009 , 49, 1486-91	11.6	64
126	Advances in the diagnosis and treatment of fungal infections of the CNS. <i>Lancet Neurology</i> , 2018 , 17, 362-372	24.1	62
125	Short course amphotericin B with high dose fluconazole for HIV-associated cryptococcal meningitis. <i>Journal of Infection</i> , 2012 , 64, 76-81	18.9	62
124	Low diversity Cryptococcus neoformans variety grubii multilocus sequence types from Thailand are consistent with an ancestral African origin. <i>PLoS Pathogens</i> , 2011 , 7, e1001343	7.6	62
123	High Cryptococcal Antigen Titers in Blood Are Predictive of Subclinical Cryptococcal Meningitis Among Human Immunodeficiency Virus-Infected Patients. <i>Clinical Infectious Diseases</i> , 2018 , 66, 686-692	11.6	61
122	A phase II randomized controlled trial adding oral flucytosine to high-dose fluconazole, with short-course amphotericin B, for cryptococcal meningitis. <i>Aids</i> , 2012 , 26, 1363-70	3.5	60
121	Tracing Genetic Exchange and Biogeography of var. at the Global Population Level. <i>Genetics</i> , 2017 , 207, 327-346	4	57
120	Dynamic ploidy changes drive fluconazole resistance in human cryptococcal meningitis. <i>Journal of Clinical Investigation</i> , 2019 , 129, 999-1014	15.9	57
119	Baseline correlation and comparative kinetics of cerebrospinal fluid colony-forming unit counts and antigen titers in cryptococcal meningitis. <i>Journal of Infectious Diseases</i> , 2005 , 192, 681-4	7	55
118	Cryptococcal immune reconstitution inflammatory syndrome. <i>Current Opinion in Infectious Diseases</i> , 2013 , 26, 26-34	5.4	53
117	Antiretroviral roll-out, antifungal roll-back: access to treatment for cryptococcal meningitis. <i>Lancet Infectious Diseases</i> , 2005 , 5, 530-1	25.5	53

116	Oral versus intravenous flucytosine in patients with human immunodeficiency virus-associated cryptococcal meningitis. <i>Antimicrobial Agents and Chemotherapy</i> , 2007 , 51, 1038-42	5.9	51
115	Histopathology of the arachnoid granulations and brain in HIV-associated cryptococcal meningitis: correlation with cerebrospinal fluid pressure. <i>Aids</i> , 2010 , 24, 405-10	3.5	50
114	A Population Genomics Approach to Assessing the Genetic Basis of Within-Host Microevolution Underlying Recurrent Cryptococcal Meningitis Infection. <i>G3: Genes, Genomes, Genetics</i> , 2017 , 7, 1165-1176	2.2	49
113	Cryptococcal antigen screening and preemptive therapy in patients initiating antiretroviral therapy in resource-limited settings: a proposed algorithm for clinical implementation. <i>Journal of the International Association of Providers of AIDS Care</i> , 2012 , 11, 374-9		48
112	Short-course High-dose Liposomal Amphotericin B for Human Immunodeficiency Virus-associated Cryptococcal Meningitis: A Phase 2 Randomized Controlled Trial. <i>Clinical Infectious Diseases</i> , 2019 , 68, 393-401	11.6	47
111	Pharmacokinetics and pharmacodynamics of fluconazole for cryptococcal meningoencephalitis: implications for antifungal therapy and in vitro susceptibility breakpoints. <i>Antimicrobial Agents and Chemotherapy</i> , 2013 , 57, 2793-800	5.9	46
110	Lumbar drainage for control of raised cerebrospinal fluid pressure in cryptococcal meningitis: case report and review. <i>Journal of Infection</i> , 2005 , 51, e221-4	18.9	45
109	A prospective longitudinal study of the clinical outcomes from cryptococcal meningitis following treatment induction with 800 mg oral fluconazole in Blantyre, Malawi. <i>PLoS ONE</i> , 2013 , 8, e67311	3.7	45
108	A prospective study of mortality from cryptococcal meningitis following treatment induction with 1200 mg oral fluconazole in Blantyre, Malawi. <i>PLoS ONE</i> , 2014 , 9, e110285	3.7	43
107	Managing cryptococcosis in the immunocompromised host. <i>Current Opinion in Infectious Diseases</i> , 2008 , 21, 596-603	5.4	39
106	Pharmacodynamics of liposomal amphotericin B and flucytosine for cryptococcal meningoencephalitis: safe and effective regimens for immunocompromised patients. <i>Journal of Infectious Diseases</i> , 2013 , 208, 351-61	7	38
105	Outcomes of cryptococcal meningitis in antiretroviral naïve and experienced patients in South Africa. <i>Journal of Infection</i> , 2010 , 60, 496-8	18.9	38
104	Long-term Mortality and Disability in Cryptococcal Meningitis: A Systematic Literature Review. <i>Clinical Infectious Diseases</i> , 2018 , 66, 1122-1132	11.6	37
103	Genomic epidemiology of <i>Cryptococcus</i> yeasts identifies adaptation to environmental niches underpinning infection across an African HIV/AIDS cohort. <i>Molecular Ecology</i> , 2017 , 26, 1991-2005	5.7	37
102	Cryptococcal Antigen Screening in Asymptomatic HIV-Infected Antiretroviral Naïve Patients in Cameroon and Evaluation of the New Semi-Quantitative Biosynex CryptoPS Test. <i>Frontiers in Microbiology</i> , 2018 , 9, 409	5.7	35
101	Leave no one behind: response to new evidence and guidelines for the management of cryptococcal meningitis in low-income and middle-income countries. <i>Lancet Infectious Diseases</i> , 2019 , 19, e143-e147	25.5	35
100	Cryptococcal antigen screening for patients initiating antiretroviral therapy: time for action. <i>Clinical Infectious Diseases</i> , 2010 , 51, 1463-5	11.6	33
99	Cryptococcal meningitis: A neglected NTD?. <i>PLoS Neglected Tropical Diseases</i> , 2017 , 11, e0005575	4.8	33

98	Immune dysfunction in HIV-seronegative, <i>Cryptococcus gattii</i> meningitis. <i>Journal of Infection</i> , 2007 , 54, e165-8	18.9	32
97	Symptomatic relapse of HIV-associated cryptococcal meningitis in South Africa: the role of inadequate secondary prophylaxis. <i>South African Medical Journal</i> , 2010 , 100, 378-82	1.5	31
96	Intrathecal production and secretion of vascular endothelial growth factor during Cryptococcal Meningitis. <i>Journal of Infectious Diseases</i> , 2004 , 190, 1310-7	7	29
95	Neurological, visual, and MRI brain scan findings in 87 South African patients with HIV-associated cryptococcal meningoencephalitis. <i>Journal of Infection</i> , 2015 , 70, 668-75	18.9	28
94	Impact of Routine Cryptococcal Antigen Screening and Targeted Preemptive Fluconazole Therapy in Antiretroviral-naïve Human Immunodeficiency Virus-infected Adults With CD4 Cell Counts. <i>Clinical Infectious Diseases</i> , 2019 , 68, 688-698	11.6	28
93	Adverse Effects and Choice between the Injectable Agents Amikacin and Capreomycin in Multidrug-Resistant Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.9	28
92	A randomised Phase II trial to evaluate the toxicity of high-dose rifampicin to treat pulmonary tuberculosis. <i>International Journal of Tuberculosis and Lung Disease</i> , 2016 , 20, 832-8	2.1	28
91	The prevalence of cryptococcal antigenemia in newly diagnosed HIV patients in a Southwest London cohort. <i>Journal of Infection</i> , 2013 , 66, 75-9	18.9	27
90	The burden of HIV-associated cryptococcal disease. <i>Aids</i> , 2009 , 23, 531-2	3.5	26
89	Dengue hemorrhagic fever with fulminant hepatic failure in an immigrant returning to Bangladesh. <i>Clinical Infectious Diseases</i> , 2003 , 37, e1-4	11.6	26
88	AMBIsome Therapy Induction Optimisation (AMBITION): High Dose AmBisome for Cryptococcal Meningitis Induction Therapy in sub-Saharan Africa: Study Protocol for a Phase 3 Randomised Controlled Non-Inferiority Trial. <i>Trials</i> , 2018 , 19, 649	2.8	26
87	Moxifloxacin population pharmacokinetics in patients with pulmonary tuberculosis and the effect of intermittent high-dose rifapentine. <i>Antimicrobial Agents and Chemotherapy</i> , 2012 , 56, 4471-3	5.9	25
86	<i>Cryptococcus neoformans</i> and cryptococcosis. <i>Journal of Infection</i> , 2000 , 41, 12-7	18.9	25
85	Immunotherapy for fungal infections. <i>Current Opinion in Microbiology</i> , 2012 , 15, 434-9	7.9	22
84	Pulmonary cryptococcosis misdiagnosed as smear-negative pulmonary tuberculosis with fatal consequences. <i>International Journal of Infectious Diseases</i> , 2010 , 14 Suppl 3, e310-2	10.5	22
83	Testing but not treating: missed opportunities and lost lives in the South African antiretroviral therapy programme. <i>Aids</i> , 2010 , 24, 1233-5	3.5	22
82	Fluconazole Monotherapy Is a Suboptimal Option for Initial Treatment of Cryptococcal Meningitis Because of Emergence of Resistance. <i>MBio</i> , 2019 , 10,	7.8	22
81	Cryptococcal-related Mortality Despite Fluconazole Preemptive Treatment in a Cryptococcal Antigen Screen-and-Treat Program. <i>Clinical Infectious Diseases</i> , 2020 , 70, 1683-1690	11.6	22

80	AMBITION-cm: intermittent high dose AmBisome on a high dose fluconazole backbone for cryptococcal meningitis induction therapy in sub-Saharan Africa: study protocol for a randomized controlled trial. <i>Trials</i> , 2015 , 16, 276	2.8	21
79	Role of capsule and interleukin-6 in long-term immune control of <i>Cryptococcus neoformans</i> infection by specifically activated human peripheral blood mononuclear cells. <i>Infection and Immunity</i> , 2006 , 74, 5302-10	3.7	21
78	Efficacy of an abbreviated induction regimen of amphotericin B deoxycholate for cryptococcal meningoencephalitis: 3 days of therapy is equivalent to 14 days. <i>MBio</i> , 2014 , 5, e00725-13	7.8	19
77	Routine cryptococcal antigen screening for HIV-infected patients with low CD4+ T-lymphocyte counts--time to implement in South Africa?. <i>South African Medical Journal</i> , 2011 , 101, 232-4	1.5	19
76	Correspondence of in vitro and in vivo fluconazole dose-response curves for <i>Cryptococcus neoformans</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2005 , 49, 3297-301	5.9	19
75	Experimental Models of Short Courses of Liposomal Amphotericin B for Induction Therapy for Cryptococcal Meningitis. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.9	18
74	The costs of providing antiretroviral therapy services to HIV-infected individuals presenting with advanced HIV disease at public health centres in Dar es Salaam, Tanzania: Findings from a randomised trial evaluating different health care strategies. <i>PLoS ONE</i> , 2017 , 12, e0171917	3.7	18
73	Is HIV-associated tuberculosis a risk factor for the development of cryptococcal disease?. <i>Aids</i> , 2010 , 24, 612-4	3.5	18
72	Tackling the emerging threat of antifungal resistance to human health.. <i>Nature Reviews Microbiology</i> , 2022 ,	22.2	18
71	XDR-TB transmission in London: Case management and contact tracing investigation assisted by early whole genome sequencing. <i>Journal of Infection</i> , 2016 , 73, 210-8	18.9	17
70	Southern African HIV Clinicians Society guideline for the prevention, diagnosis and management of cryptococcal disease among HIV-infected persons: 2019 update. <i>Southern African Journal of HIV Medicine</i> , 2019 , 20, 1030	1.4	17
69	Early clinical and subclinical visual evoked potential and Humphrey® visual field defects in cryptococcal meningitis. <i>PLoS ONE</i> , 2012 , 7, e52895	3.7	16
68	Immune correlates of HIV-associated cryptococcal meningitis. <i>PLoS Pathogens</i> , 2017 , 13, e1006207	7.6	15
67	Forgotten but not gone: HIV-associated cryptococcal meningitis. <i>Lancet Infectious Diseases</i> , 2016 , 16, 756-758	25.5	14
66	Large volume lumbar punctures in cryptococcal meningitis clear cryptococcal antigen as well as lowering pressure. <i>Journal of Infection</i> , 2011 , 63, 484-6	18.9	14
65	Cryptococcal Antigen in Serum and Cerebrospinal Fluid for Detecting Cryptococcal Meningitis in Adults Living With Human Immunodeficiency Virus: Systematic Review and Meta-Analysis of Diagnostic Test Accuracy Studies. <i>Clinical Infectious Diseases</i> , 2021 , 72, 1268-1278	11.6	14
64	Brief Report: Point of Care Cryptococcal Antigen Screening: Pipetting Finger-Prick Blood Improves Performance of Immunomycologics Lateral Flow Assay. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018 , 78, 574-578	3.1	13
63	Single-Dose Liposomal Amphotericin B Treatment for Cryptococcal Meningitis.. <i>New England Journal of Medicine</i> , 2022 , 386, 1109-1120	59.2	13

62	Drug resistant TB: UK multicentre study (DRUMS): Treatment, management and outcomes in London and West Midlands 2008-2014. <i>Journal of Infection</i> , 2017 , 74, 260-271	18.9	12
61	Evaluation of a Novel Semiquantitative Cryptococcal Antigen Lateral Flow Assay in Patients with Advanced HIV Disease. <i>Journal of Clinical Microbiology</i> , 2020 , 58,	9.7	12
60	Optimal doses of rifampicin in the standard drug regimen to shorten tuberculosis treatment duration and reduce relapse by eradicating persistent bacteria. <i>Journal of Antimicrobial Chemotherapy</i> , 2018 , 73, 724-731	5.1	12
59	Primary cytomegalovirus infectious colitis complicating Crohn's disease successfully treated with oral valganciclovir. <i>Journal of Crohn's and Colitis</i> , 2010 , 4, 199-202	1.5	10
58	One-year Mortality Outcomes From the Advancing Cryptococcal Meningitis Treatment for Africa Trial of Cryptococcal Meningitis Treatment in Malawi. <i>Clinical Infectious Diseases</i> , 2020 , 70, 521-524	11.6	10
57	Healthcare Costs and Life-years Gained From Treatments Within the Advancing Cryptococcal Meningitis Treatment for Africa (ACTA) Trial on Cryptococcal Meningitis: A Comparison of Antifungal Induction Strategies in Sub-Saharan Africa. <i>Clinical Infectious Diseases</i> , 2019 , 69, 588-595	11.6	9
56	Very low levels of 25-hydroxyvitamin D are not associated with immunologic changes or clinical outcome in South African patients with HIV-associated cryptococcal meningitis. <i>Clinical Infectious Diseases</i> , 2014 , 59, 493-500	11.6	9
55	Addition of Flucytosine to Fluconazole for the Treatment of Cryptococcal Meningitis in Africa: A Multicountry Cost-effectiveness Analysis. <i>Clinical Infectious Diseases</i> , 2020 , 70, 26-29	11.6	8
54	Should antiretroviral therapy be delayed for 10 weeks for patients treated with fluconazole for cryptococcal meningitis?. <i>Clinical Infectious Diseases</i> , 2010 , 51, 986-7; author reply 987-9	11.6	7
53	Recent advances in managing HIV-associated cryptococcal meningitis. <i>F1000Research</i> , 2019 , 8,	3.6	7
52	A Population Pharmacokinetic Analysis Shows that Arylacetamide Deacetylase (AADAC) Gene Polymorphism and HIV Infection Affect the Exposure of Rifapentine. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 63,	5.9	6
51	Ischemic stroke as a complication of cryptococcal meningitis and immune reconstitution inflammatory syndrome: a case report. <i>BMC Infectious Diseases</i> , 2018 , 18, 520	4	6
50	Time to embrace access programmes for medicines: lessons from the South African flucytosine access programme. <i>International Journal of Infectious Diseases</i> , 2020 , 95, 459-461	10.5	5
49	Amphotericin B plus fluconazole for HIV-associated cryptococcal meningitis. <i>Clinical Infectious Diseases</i> , 2009 , 48, 1784-6	11.6	5
48	Diagnostic Accuracy of the Biosynex CryptoPS Cryptococcal Antigen Semiquantitative Lateral Flow Assay in Patients with Advanced HIV Disease. <i>Journal of Clinical Microbiology</i> , 2020 , 59,	9.7	5
47	Presentations and outcomes of central nervous system TB in a UK cohort: The high burden of neurological morbidity. <i>Journal of Infection</i> , 2021 , 82, 90-97	18.9	5
46	Ending deaths from HIV-related cryptococcal meningitis by 2030. <i>Lancet Infectious Diseases</i> , 2021 , 21, 16-18	25.5	5
45	Cryptococcal meningitis in apparently immunocompetent patients: association with idiopathic CD4+ lymphopenia. <i>Practical Neurology</i> , 2018 , 18, 166-169	2.4	5

44	Cryptococcal meningitis. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2017 , 78, C125-C128	4
43	Access to antifungal medicines in resource-poor countries - authors reply. <i>Lancet Infectious Diseases, The</i> , 2014 , 14, 371	25.5 4
42	Cerebrospinal fluid HIV-1 viral load during treatment of cryptococcal Meningitis. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2010 , 53, 668-9	3.1 4
41	Positive predictive value of the UK clinical case definition for H1N1/09 (swine) influenza. <i>Journal of Infection</i> , 2010 , 60, 405-7	18.9 4
40	Genome-Wide Association Study Identifies Novel Colony Stimulating Factor 1 Locus Conferring Susceptibility to Cryptococcosis in Human Immunodeficiency Virus-Infected South Africans. <i>Open Forum Infectious Diseases</i> , 2020 , 7, ofaa489	1 4
39	A population genomics approach to assessing the genetic basis of within-host microevolution underlying recurrent cryptococcal meningitis infection	4
38	A pragmatic approach to managing antiretroviral therapy-experienced patients diagnosed with HIV-associated cryptococcal meningitis: impact of antiretroviral therapy adherence and duration. <i>Aids</i> , 2020 , 34, 1425-1428	3.5 4
37	Cryptococcal Meningitis Screening and Community-based Early Adherence Support in People With Advanced Human Immunodeficiency Virus Infection Starting Antiretroviral Therapy in Tanzania and Zambia: A Cost-effectiveness Analysis. <i>Clinical Infectious Diseases</i> , 2020 , 70, 1652-1657	11.6 4
36	Transcriptional Profiling of Patient Isolates Identifies a Novel TOR/Starvation Regulatory Pathway in Cryptococcal Virulence. <i>MBio</i> , 2018 , 9,	7.8 4
35	Systemic fungal infections. <i>Medicine</i> , 2014 , 42, 26-30	0.6 3
34	Prevention of AIDS-associated cryptococcosis in resource-poor areas. <i>Lancet Infectious Diseases, The</i> , 2011 , 11, 892-4	25.5 3
33	Reducing Mortality Associated with Opportunistic Infections among Patients with Advanced HIV Infection in Sub-Saharan Africa: Reply to DiNubile. <i>Clinical Infectious Diseases</i> , 2009 , 49, 812-813	11.6 3
32	Determine TB-LAM point-of-care tuberculosis assay predicts poor outcomes in outpatients during their first year of antiretroviral therapy in South Africa. <i>BMC Infectious Diseases</i> , 2020 , 20, 555	4 3
31	AMBIsome Therapy Induction Optimisation (AMBITION): High dose AmBisome for cryptococcal meningitis induction therapy in sub-Saharan Africa: economic evaluation protocol for a randomised controlled trial-based equivalence study. <i>BMJ Open</i> , 2019 , 9, e026288	3 3
30	Insights from compassionate use of tocilizumab for COVID-19 to inform appropriate design of randomised controlled trials. <i>British Journal of Clinical Pharmacology</i> , 2021 , 87, 1584-1586	3.8 3
29	Fungal Burden and Raised Intracranial Pressure Are Independently Associated With Visual Loss in Human Immunodeficiency Virus-Associated Cryptococcal Meningitis. <i>Open Forum Infectious Diseases</i> , 2021 , 8, ofab066	1 3
28	The treatment of a pregnant HIV positive patient with cryptococcal meningitis in Malawi. Case report and review of treatment options. <i>Medical Mycology Case Reports</i> , 2018 , 19, 9-12	1.7 3
27	Reply to Rajasingham and Boulware. <i>Clinical Infectious Diseases</i> , 2019 , 69, 732-735	11.6 2

26	Poor specificity of urinary cryptococcal antigen testing: Reply to Drain et al. Prevalence of cryptococcal antigenuria at initial HIV diagnosis in KwaZulu-Natal. <i>HIV Medicine</i> , 2018 , 19, e47-e48	2.7	2
25	Evaluation of a pro-active strategy for managing tuberculosis-HIV co-infection in a UK tertiary care setting. <i>International Journal of STD and AIDS</i> , 2013 , 24, 263-8	1.4	2
24	Reply to Pasqualotto. <i>Clinical Infectious Diseases</i> , 2008 , 47, 1110-1111	11.6	2
23	Systemic fungal infections. <i>Medicine</i> , 2005 , 33, 116-119	0.6	2
22	Cryptococcosis in Asia 287-297		2
21	Population genomics of <i>Cryptococcus neoformans</i> var. <i>grubii</i> reveals new biogeographic relationships and finely maps hybridization		2
20	The Lived Experience Of Participants in an African Randomised trial (LEOPARD): protocol for an in-depth qualitative study within a multisite randomised controlled trial for HIV-associated cryptococcal meningitis. <i>BMJ Open</i> , 2021 , 11, e039191	3	2
19	Effect of oral fluconazole 1200 mg/day on QT interval in African adults with HIV-associated cryptococcal meningitis. <i>Aids</i> , 2018 , 32, 2259-2261	3.5	2
18	Establishing targets for advanced HIV disease: A call to action. <i>Southern African Journal of HIV Medicine</i> , 2021 , 22, 1266	1.4	2
17	Itraconazole and antiretroviral therapy: strategies for empirical dosing - Author Q reply. <i>Lancet Infectious Diseases</i> , 2017 , 17, 1123-1124	25.5	1
16	Systemic fungal infections. <i>Medicine</i> , 2009 , 37, 660-664	0.6	1
15	Rapid urine-based screening tests increase the yield of same-day tuberculosis diagnoses among patients living with advanced HIV disease. <i>Aids</i> , 2022 ,	3.5	1
14	The <i>Cryptococcus neoformans</i> Titan cell is an inducible and regulated morphotype underlying pathogenesis		1
13	Differences in human immunodeficiency virus-1C viral load and drug resistance mutation between plasma and cerebrospinal fluid in patients with human immunodeficiency virus-associated cryptococcal meningitis in Botswana. <i>Medicine (United States)</i> , 2020 , 99, e22606	1.8	1
12	HIV-1C and Variation in the Cerebrospinal Fluid and Plasma of Patients with HIV-Associated Cryptococcal Meningitis in Botswana. <i>Viruses</i> , 2020 , 12,	6.2	1
11	Equity in clinical trials for HIV-associated cryptococcal meningitis: A systematic review of global representation and inclusion of patients and researchers. <i>PLoS Neglected Tropical Diseases</i> , 2021 , 15, e0009376	4.8	1
10	Short-term Mortality Outcomes of HIV-Associated Cryptococcal Meningitis in Antiretroviral Therapy-Naïve and -Experienced Patients in Sub-Saharan Africa. <i>Open Forum Infectious Diseases</i> , 2021 , 8, ofab397	1	1
9	Decision making in a clinical trial for a life-threatening illness: Therapeutic expectation, not misconception. <i>Social Science and Medicine</i> , 2022 , 305, 115082	5.1	0

- 8 Cryptococcus: Spectrum of Disease and Treatment **2010**, 145-165
- 7 Reply to Lee and Newton. *Clinical Infectious Diseases*, **2012**, 55, 1745-1746 11.6
- 6 Ophthalmic features of HIV associated cryptococcal meningitis in Malawian Adults: an observational study. *Wellcome Open Research*, **4**, 83 4.8
- 5 Ophthalmic features of HIV associated cryptococcal meningitis in Malawian Adults: an observational study. *Wellcome Open Research*, **4**, 83 4.8
- 4 Management of Cryptococcal Meningoencephalitis in Both Developed and Developing Countries 565-584
- 3 Low-cerebrospinal fluid white cell counts and mortality in HIV-associated pneumococcal meningitis. *Aids*, **2019**, 33, 1539-1541 3.5
- 2 Co-prevalent infections in adults with HIV-associated cryptococcal meningitis are associated with an increased risk of death: a nested analysis of the Advancing Cryptococcal meningitis Treatment for Africa (ACTA) cohort. *Wellcome Open Research*, **6**, 19 4.8
- 1 Neurological deterioration in a patient with HIV-associated cryptococcal meningitis initially improving on antifungal treatment: a case report of coincidental racemose neurocysticercosis. *BMC Infectious Diseases*, **2021**, 21, 724 4